Impact of the 2017 FDA Drug Safety Communication on Codeine and Tramadol Dispensing to Children

被引：2
|
作者：
Renny, Madeline H. [1 ,2 ,3 ,4 ]
Jent, Victoria [4 ]
Townsend, Tarlise [4 ]
Cerda, Magdalena [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10019 USA
[2] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10019 USA
[3] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10019 USA
[4] NYU, Dept Populat Hlth, Grossman Sch Med, Ctr Opioid Epidemiol & Policy, New York, NY USA
来源：
PEDIATRICS | 2022年 / 150卷 / 05期
基金：
美国医疗保健研究与质量局;
关键词：
D O I：
10.1542/peds.2021-055887
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Impact of the FDA Safety Communication on Prescription Trends of Clopidogrel in Combination with Proton Pump Inhibitors
    Guerin, Annie
    Mody, Reema
    Carter, Valerie
    Wu, Eric
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S36 - S37
  • [22] The 2010 FDA Drug Safety Recommendations and LABA Dispensing Pattern Changes in Adult Asthma Patients During 2003-2012
    Zhou, Esther H.
    Kang, Elizabeth M.
    Seymour, Sally
    Goulding, Margie
    Iyasu, Solomon
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 70 - 70
  • [23] FDA Issues Early Communication About Ongoing Safety Review of Weight Loss Drug Orlistat
    Peek, Richard
    Reddy, K. Rajender
    GASTROENTEROLOGY, 2009, 137 (05) : 1546 - 1547
  • [24] A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children
    Hedenmalm, Karin
    Blake, Kevin
    Donegan, Katherine
    Macia, Miguel-Angel
    Gil, Miguel
    Williams, Julie
    Montero, Dolores
    Candore, Gianmario
    Morales, Daniel
    Kurz, Xavier
    Arlett, Peter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (08) : 1086 - 1096
  • [25] FDA Drug Safety Announcements' Impact on Use of Bisphosphonates Among Patients with Hip Fracture
    Kim, Seoyoung C.
    Kim, Dae Hyun
    Eddings, Wesley
    Mogun, Helen
    Polinski, Jennifer M.
    Franklin, Jessica M.
    Solomon, Daniel H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 19 - 19
  • [26] The impact of the FDA 2014 power morcellation safety communication on CHS gynecologic surgeon practice patterns
    Taylor, G. B.
    Earles, E.
    Kaczmarski, K.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 218 (02) : S905 - S905
  • [27] Changes in Long-acting β-agonist Utilization After the FDA's 2010 Drug Safety Communication
    Hartung, Daniel M.
    Middleton, Luke
    Markwardt, Sheila
    Williamson, Kaylee
    Ketchum, Kathy
    CLINICAL THERAPEUTICS, 2015, 37 (01) : 114 - 123
  • [28] Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for Aortic Aneurysm Risk
    Li, Catherine
    Mercuro, Nicholas J.
    Chapin, Ryan W.
    Gold, Howard S.
    McCoy, Christopher
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (09)
  • [29] 2017-2018 Hematology Drug Approvals at the Food and Drug Administration (FDA): Communication of Patient-Reported Outcomes (PRO) Information in FDA Clinical Reviews and Prescribing Information (PI)
    Kim, Janice
    Kanapuru, Bindu
    Roydhouse, Jessica K.
    Farrell, Ann T.
    Bouchkouj, Najat
    Ezzeldin, Hussein
    Kluetz, Paul
    BLOOD, 2019, 134
  • [30] Pelvic organ prolapse surgical management in Portugal and FDA safety communication have an impact on vaginal mesh
    Mascarenhas, Teresa
    Mascarenhas-Saraiva, Miguel, Jr.
    Ricon-Ferraz, Amelia
    Nogueira, Paula
    Lopes, Fernando
    Freitas, Alberto
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2015, 26 (01) : 113 - 122
12345